Antineoplaston Therapy in Treating Patients With Cancer of Unknown Primary Origin
Status:
Terminated
Trial end date:
2005-02-02
Target enrollment:
Participant gender:
Summary
Current therapies for Cancer of Unknown Primary Origin provide very limited benefit to the
patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove
beneficial in the treatment of Cancer of Unknown Primary Origin.
PURPOSE: This study is being performed to determine the effects (good and bad) that
Antineoplaston therapy has on patients with Cancer of Unknown Primary Origin.